FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W34668368> ?p ?o ?g. }

• W34668368 endingPage "395" @default.
• W34668368 startingPage "395" @default.
• W34668368 abstract "Methylation of DNA at 5-position of cytosine, catalyzed by DNA methyltransferases, is the predominant epigenetic modification in mammals. Aberrations in methylation play a causal role in a variety of diseases, including cancer. Recent studies have established that like mutation, methylation-mediated gene silencing often leads to tumorigenesis. Paradoxically, genome-wide DNA hypomethylation may also play a causal role in carcinogenesis by inducing chromosomal instability and spurious gene expression. Since methylation does not alter DNA base sequence, much attention has been focused recently on developing small molecule inhibitors of DNA methyltransferases that can potentially be used as anticancer agents. Vidaza (5-azacytidine), marketed by Pharmion (Boulder, CO, USA), was the first DNA methyltransferase inhibitor approved by the U.S. Food and Drug Administration (FDA) for chemotherapy against myelodysplastic syndrome (MDS), a heterogeneous bone marrow disorder. Recently MGI Pharma Inc. (Bloomington, MN, USA) got FDA approval to market Dacogen (5-aza-2'-deoxycytidine, or decitabine) for treating MDS patients. These drugs were used earlier against certain anemias to induce expression of fetal globin genes. Interest in clinical trials of these drugs as anticancer agents has been renewed only recently because of reversal of methylation-mediated silencing of critical genes in cancer. Clinical trials have shown that both drugs have therapeutic potential against leukemia such as MDS, acute myeloid leukemia, chronic myelogenous leukemia and chronic myelomonocytic leukemia. In contrast, their effectiveness with solid tumors appears to be less promising, which challenges researchers to develop inhibitors with more efficacy and less toxicity. The major hindrance of their usage as anticancer agents is their instability in vivo as well as the toxicity secondary to their excessive incorporation into DNA, which causes cell cycle arrest. Gene expression profiling in cancer cells revealed that antineoplastic property of these drugs is mediated through both methylation-dependent and -independent pathways. Recently, we have shown that treatment of cancer cells with these cytidine analogues also induces proteasomal degradation of DNA methyltransferase 1, the ubiquitously expressed enzyme upregulated in almost all cancer cells. Development of related stable drugs that can facilitate gene activation in cancer cells by enhancing degradation of DNA methyltransferases without being incorporated into DNA would be ideal for chemotherapy. In this monograph we review historical perspective and recent advances on the molecular mechanisms of action and clinical applications of these DNA hypomethylating agents." @default.
• W34668368 created "2016-06-24" @default.
• W34668368 creator A5081920761 @default.
• W34668368 creator A5084279554 @default.
• W34668368 date "2007-01-01" @default.
• W34668368 modified "2023-10-09" @default.
• W34668368 title "DNA methyltransferase as targets for cancer therapy" @default.
• W34668368 doi "https://doi.org/10.1358/dot.2007.43.6.1062666" @default.
• W34668368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17612710" @default.
• W34668368 hasPublicationYear "2007" @default.
• W34668368 type Work @default.
• W34668368 sameAs 34668368 @default.
• W34668368 citedByCount "119" @default.
• W34668368 countsByYear W346683682012 @default.
• W34668368 countsByYear W346683682013 @default.
• W34668368 countsByYear W346683682014 @default.
• W34668368 countsByYear W346683682015 @default.
• W34668368 countsByYear W346683682016 @default.
• W34668368 countsByYear W346683682017 @default.
• W34668368 countsByYear W346683682018 @default.
• W34668368 countsByYear W346683682019 @default.
• W34668368 countsByYear W346683682020 @default.
• W34668368 countsByYear W346683682021 @default.
• W34668368 countsByYear W346683682022 @default.
• W34668368 countsByYear W346683682023 @default.
• W34668368 crossrefType "journal-article" @default.
• W34668368 hasAuthorship W34668368A5081920761 @default.
• W34668368 hasAuthorship W34668368A5084279554 @default.
• W34668368 hasConcept C104317684 @default.
• W34668368 hasConcept C119056186 @default.
• W34668368 hasConcept C121608353 @default.
• W34668368 hasConcept C126322002 @default.
• W34668368 hasConcept C150194340 @default.
• W34668368 hasConcept C190727270 @default.
• W34668368 hasConcept C203014093 @default.
• W34668368 hasConcept C2776239401 @default.
• W34668368 hasConcept C2778461978 @default.
• W34668368 hasConcept C2779979206 @default.
• W34668368 hasConcept C2780007613 @default.
• W34668368 hasConcept C2780235182 @default.
• W34668368 hasConcept C2780817109 @default.
• W34668368 hasConcept C33288867 @default.
• W34668368 hasConcept C41091548 @default.
• W34668368 hasConcept C502942594 @default.
• W34668368 hasConcept C54355233 @default.
• W34668368 hasConcept C555283112 @default.
• W34668368 hasConcept C71924100 @default.
• W34668368 hasConcept C86803240 @default.
• W34668368 hasConcept C91965660 @default.
• W34668368 hasConceptScore W34668368C104317684 @default.
• W34668368 hasConceptScore W34668368C119056186 @default.
• W34668368 hasConceptScore W34668368C121608353 @default.
• W34668368 hasConceptScore W34668368C126322002 @default.
• W34668368 hasConceptScore W34668368C150194340 @default.
• W34668368 hasConceptScore W34668368C190727270 @default.
• W34668368 hasConceptScore W34668368C203014093 @default.
• W34668368 hasConceptScore W34668368C2776239401 @default.
• W34668368 hasConceptScore W34668368C2778461978 @default.
• W34668368 hasConceptScore W34668368C2779979206 @default.
• W34668368 hasConceptScore W34668368C2780007613 @default.
• W34668368 hasConceptScore W34668368C2780235182 @default.
• W34668368 hasConceptScore W34668368C2780817109 @default.
• W34668368 hasConceptScore W34668368C33288867 @default.
• W34668368 hasConceptScore W34668368C41091548 @default.
• W34668368 hasConceptScore W34668368C502942594 @default.
• W34668368 hasConceptScore W34668368C54355233 @default.
• W34668368 hasConceptScore W34668368C555283112 @default.
• W34668368 hasConceptScore W34668368C71924100 @default.
• W34668368 hasConceptScore W34668368C86803240 @default.
• W34668368 hasConceptScore W34668368C91965660 @default.
• W34668368 hasIssue "6" @default.
• W34668368 hasLocation W346683681 @default.
• W34668368 hasLocation W346683682 @default.
• W34668368 hasOpenAccess W34668368 @default.
• W34668368 hasPrimaryLocation W346683681 @default.
• W34668368 hasRelatedWork W1575781057 @default.
• W34668368 hasRelatedWork W1974512900 @default.
• W34668368 hasRelatedWork W2032611473 @default.
• W34668368 hasRelatedWork W2065576507 @default.
• W34668368 hasRelatedWork W2167485228 @default.
• W34668368 hasRelatedWork W2316427340 @default.
• W34668368 hasRelatedWork W2319910057 @default.
• W34668368 hasRelatedWork W2348621912 @default.
• W34668368 hasRelatedWork W4286817035 @default.
• W34668368 hasRelatedWork W2189342016 @default.
• W34668368 hasVolume "43" @default.
• W34668368 isParatext "false" @default.
• W34668368 isRetracted "false" @default.
• W34668368 magId "34668368" @default.
• W34668368 workType "article" @default.